Heart failure hospitalization risk associated with use of two classes of oral antidiabetic medications: an observational, real-world analysis

Table 2 Comparison of unadjusted risk of heart failure hospitalization in two study cohorts before and after matching

	Overall unmatched cohorts		Matched cohorts
	DPP4 n = 32,060	SGLT2 n = 5467	DPP4 n = 9798	SGLT2 n = 4899
Follow up length (months)
Median	23.8	23.0	24.0	22.9
25th, 75th percentiles	9.7, 32.0	10.6, 28.3	10.5, 32.1	10.5, 30.8
Maximum	42.9	42.7	42.9	42.7
Exposure to index medication class
Average number of fills	10.2	11.3	10.4	11.2
Average number of days covered	359	357	365	354
Patients w/heart failure hospitalization	1734	109	307	96
Proportion of patients w/heart failure hospitalization (%)	5.4	2.0	3.1	2.0
Person-years of follow up, n	58,018	9192	17,981	8228
Event rate (95% CI) per 100 person years	2.99 (2.85–3.13)	1.19 (0.98–1.43)	1.71 (1.53–1.91)	1.17 (0.96–1.43)
HR (95% CI), unadjusted	0.39 (0.32–0.48); p < .001		0.68 (0.54–0.86); p = .001

CI confidence interval, DPP4 dipeptidyl peptidase-4, HR hazard ratio, SGLT2 sodium–glucose co-transporter 2

ISSN: 1475-2840